Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
Status:
Withdrawn
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study will be to prospectively evaluate the response of a continuous
infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and
maintain the AT activity within a specified range in adult patients that require
extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and cardiac
surgery.